Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14–16, 2010, São Paulo, Brazil

Lópes, Renato D.; Becker, Richard C.; Alexander, John H.; Armstrong, Paul W.; Califf, Robert M.; Chan, Mark Y.; Crowther, Mark; Granger, Christopher B.; Harrington, Robert A.; James, Stefan; Jolicœur, E. Marc; Mahaffey, Kenneth W.; Newby, L. Kristin; Peterson, Eric D.; Pieper, Karen S.; Werf, Frans Van de; Wallentin, Lars; White, Harvey D.; Carvalho, Antônio Carlos; Giraldez, Roberto R.; Guimarães, Hélio Penna; Nader, Helena B.; Kalil, Renato A. K.; Bizzachi, Joyce Maria Annichino; Lopes, Antônio Carlos; García, David

doi:10.1007/s11239-011-0592-7

Cited by 2 publications

(1 citation statement)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although a pharmacokinetic and pharmacogenetic interaction has been described, the clinical consequences of this combination and the relationship to adverse clinical outcomes such as secondary CVD-events seem to be minimal or non-existent [18]. This assessment is supported by our observations, although the limited sample size and the relatively rare use of clopidogrel a decade ago in this routine clinical care setting of our study population may only allow excluding a strong effect.…”

Section: Discussionsupporting

confidence: 62%

Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical care

Rothenbacher

Hoffmann

Breitling

et al. 2013

BMC Cardiovasc Disord

View full text Add to dashboard Cite

BackgroundCYP2C19*2 polymorphism is related to metabolizer phenotypes resulting in reduced effectiveness in converting the antiplatelet drug clopidogrel to active drug. An association of the genotype itself with adverse outcomes is discussed. We investigated the prognostic value of carriage of the CYP2C19*2 allele in a high risk group of patients with prevalent coronary heart disease (CHD) at baseline during long-term follow-up under conditions of routine clinical care.MethodsIn n=1050 patients with stable CHD at baseline genotyping of CYP2C19 allele *2 (rs4244285; 681G>A) was performed. The Cox-proportional hazards model was employed to investigate the association of CYPC19*2 allele status with cardiovascular disease (CVD) events during eight year follow-up. The analysis was also performed in patients who did not take clopidogrel or ticlopidin.ResultsOnly the very few patients homozygous for a loss-of-function variant of CYP2C19, allele *2 (2.6%), had a statistically significantly higher incidence rate for secondary CVD events during long-term follow-up than wild-type carriers (50.8 versus 21.5 per 1000 patients years; rate for heterozygous carries 17.2 per 1000 patient years). The hazard ratio after adjustment for covariates compared to the wild-type carriers was 2.59 (95% confidence interval (CI) 1.27-5.28) and 0.80 (95% CI 0.52-1.23) for homozygous and heterozygous allele carriers, respectively.ConclusionsIn this medium-size group of patients with stable CHD homozygous carriers of the loss-of-function allele CYP2C19*2 were at increased risk for subsequent CVD events during 8 year follow-up independent of other risk factors. As only few patients carried the homozygous loss-of-function variant and we found overall no evidence for improved clinical utility, a benefit of genotyping in this patient population seems unlikely.

show abstract

Section: Discussionsupporting

confidence: 62%

Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical care

Rothenbacher

Hoffmann

Breitling

et al. 2013

BMC Cardiovasc Disord

View full text Add to dashboard Cite

show abstract

Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20–21, 2011, Salvador, Bahia, Brazil

Lópes

Becker

Newby

et al. 2012

J Thromb Thrombolysis

View full text Add to dashboard Cite

Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14–16, 2010, São Paulo, Brazil

Abstract: To discuss and share knowledge around advances in the care of patients with thrombotic disorders, the Third International Symposium of Thrombosis and Anticoagulation was held in São Paulo, Brazil, from October 14-16, 2010.

Cited by 2 publications

References 79 publications

Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical care

Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical care

Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20–21, 2011, Salvador, Bahia, Brazil

Contact Info

Product

Resources

About